The objective of this OHE Consulting Report was to outline trends in Scottish Medicines Committee (SMC) advice decisions for medicines for the period October 2009 to September 2015. This report was initiated and funded by Pfizer Ltd. It specifically considers whether there were changes in the trends due to the adoption of new policies by the SMC, namely the increased use of modifiers when assessing cost-effectiveness (e.g.
Feng, Y., Devlin, N., Shah, K., Mulhern, B. and Van Hout, B.
Please note that a revised version of this paper has been accepted for publication and is forthcoming in Health Economics. There are some differences between the value set reported in the Health Economics version and the provisional value set reported in the OHE Research Paper version. Any use of the content of these materials is the sole responsibility of the user.
Devlin, N., Shah, K., Feng, Y., Mulhern, B. and Van Hout, B.
Please note that a revised version of this paper has been accepted for publication and is forthcoming in Health Economics. There are some differences between the value set reported in the Health Economics version and the provisional value set reported in the OHE Research Paper version.
This paper presents a model to capture the behaviour of health sector decision makers when making resource allocation decisions on the level and mix of healthcare production, while taking into consideration the maximum expenditure (budget) allowed by the government or the health system regulator.
The paper seeks to address two perennial policy and practical discussions in the UK National Health Service (NHS) (and elsewhere): how to cope with financial austerity; and the opportunity costs of reimbursing new health technologies.
Cole, A., Garrison, L., Mestre-Ferrandiz, J. and Towse, A.
The objective of this OHE Consulting Report was to understand and develop a view on the core principles that should govern how Real-World Data (RWD) is accessed or generated, and used credibly to produce or generate Real-World Evidence (RWE), thereby working toward a set of “international standards”.
Mestre-Ferrandiz, J., Towse, A., Dellamano, R. and Pistollato, M.
Multi-indication pricing (MIP) involves setting a different price for each major indication approved for a medicine. As value is likely to differ across major indications, if prices paid for on-patent medicines are to reflect their value, then multi-indication medicines should have different prices across major indication, reflecting different values.
Why might the launch price of a new drug be a poor indicator of future expenditure for a drug? Which are the factors that determine the future prices and market shares of a drug? Understanding the answers to these questions can be crucial when conducting cost-effectiveness analyses i.e. when studying if it is desirable to publicly fund reimburse a new drug. This paper models and studies the price of a new drug along its life-cycle, from launch to discontinuation, to understand how the price of the drug evolves and to help inform cost-effectiveness evaluations.